ImmunoGen, Inc. (IMGN) Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor Target  
7/11/2012 10:12:06 AM

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN853 product candidate. The Phase I trial initiated evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics and anticancer activity of this TAP compound in patients with ovarian cancer or other solid tumors that over-express FOLR1 (also known as folate receptor alpha), including non-small cell lung cancer (NSCLC). Once the maximum tolerated dose (MTD) of IMGN853 is established, the activity of the compound will be evaluated in disease-specific patient cohorts.